论文部分内容阅读
目的:评价中成药平消胶囊与放疗同步治疗鼻咽癌疗效,探讨其增敏机制。方法: 1999年1月~2004年1月将188例中晚期鼻咽癌患者随机分为两组:治疗组(放疗+平消胶囊)94例,对照组(单纯放疗) 94例。两组采用医用直线加速器产生X线及β线常规外照射,包括鼻咽部原发灶及颅底、颈部转移灶。原发灶DT66~70Gy,颈部转移灶DT60~76Gy(或预防照射DT50Gy)。治疗组放疗前3天开始口服平消胶囊8粒, 3次/日,连用至放疗结束。结果:半量疗效及全量(结束时)消失率:治疗组原发灶84.0%及93.6%,颈部转移灶80.9%及93.6%;对照组原发灶54.3%及62.8%,颈部转移灶52.1%及61.7%。半量疗效及全量消失率比原发灶提高29.8%及30.9%,转移灶提高28 7%及31 9%。结论:平消胶囊与放疗同步治疗鼻咽癌与单纯放疗两组间有显著差异(P<0.01),提示平消胶囊有放疗增敏作用。
OBJECTIVE: To evaluate the curative effect of concurrent treatment of Pingxiao capsule and radiotherapy for nasopharyngeal carcinoma and to explore the mechanism of its sensitization. Methods: From January 1999 to January 2004, 188 patients with advanced nasopharyngeal carcinoma were randomly divided into two groups: 94 in the treatment group (radiotherapy + Pingxiao capsule) and 94 in the control group (radiotherapy alone). Two sets of medical linear accelerator to produce X-ray and β-ray conventional external irradiation, including the primary nasopharyngeal and skull base, neck metastases. Primary tumor DT66 ~ 70Gy, neck metastases DT60 ~ 76Gy (or prevent irradiation DT50Gy). Three days before treatment, the treatment group started oral administration of Pingxiao Capsule (n = 8) 3 times a day for the end of radiotherapy. Results: The curative effect of half amount and the disappearance rate of total amount (end) were 84.0% and 93.6% in primary treatment group, 80.9% and 93.6% in primary cervical disease group, 54.3% and 62.8% in primary control group, 52.1 % And 61.7% respectively. Half dose efficacy and total disappearance rate increased by 29.8% and 30.9% compared with the primary tumor, metastasis increased by 28 7% and 31 9%. Conclusion: There is a significant difference between the two groups (P <0.01) for the simultaneous treatment of nasopharyngeal carcinoma and radiotherapy alone by Pingxiao capsule and radiotherapy, suggesting that Pingxiao capsule has radiosensitivity effect.